

# Naoto Takahashi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5629997/publications.pdf>

Version: 2024-02-01

125  
papers

2,499  
citations

218381

26  
h-index

233125

45  
g-index

130  
all docs

130  
docs citations

130  
times ranked

2864  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Downregulation of miR-26 promotes invasion and metastasis via targeting interleukin-22 in cutaneous T-cell lymphoma. <i>Cancer Science</i> , 2022, 113, 1208-1219.  | 1.7 | 6         |
| 2  | Relationship between achievement of major molecular response or deep molecular response and nilotinib plasma concentration in patients with chronic myeloid leukemia receiving first-line nilotinib therapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 609-616. | 1.1 | 2         |
| 3  | Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis. <i>International Journal of Hematology</i> , 2022, 115, 838-851.   | 0.7 | 6         |
| 4  | Evaluation of the plasma concentration of ponatinib in a chronic myeloid leukaemia patient with ponatinib intolerance. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 219-222.  | 0.7 | 2         |
| 5  | The BCRP inhibitor febuxostat enhances the effect of nilotinib by regulation of intracellular concentration. <i>International Journal of Hematology</i> , 2021, 113, 100-105.   | 0.7 | 7         |
| 6  | Effects of proprotein convertase subtilisin/kexin type 9 and nilotinib plasma concentrations on nilotinib-induced hypercholesterolaemia in patients with chronic myeloid leukaemia. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 382-387.                 | 0.7 | 3         |
| 7  | Effects of SLC22A2 808G>T polymorphism and bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving bosutinib therapy. <i>Scientific Reports</i> , 2021, 11, 6362.  | 1.6 | 4         |
| 8  | Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update. <i>Leukemia</i> , 2021, 35, 1631-1642.   | 3.3 | 18        |
| 9  | Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia. <i>Nature Communications</i> , 2021, 12, 2833.  | 5.8 | 39        |
| 10 | The Combination of Interferon-Alpha and Ponatinib Enables Faster and Deeper Molecular Responses in Patient with De Novo Blast Crisis of CML: Interferon-Alpha May Return as a CML Treatment. <i>Case Reports in Hematology</i> , 2021, 2021, 1-4.                             | 0.3 | 2         |
| 11 | Multiple myeloma with t(11;14)-associated immature phenotype has lower CD38 expression and higher BCL2 dependence. <i>Cancer Science</i> , 2021, 112, 3645-3654.  | 1.7 | 8         |
| 12 | IL-6 Generated from Human Hematopoietic Stem and Progenitor Cells through TLR4 Signaling Promotes Emergency Granulopoiesis by Regulating Transcription Factor Expression. <i>Journal of Immunology</i> , 2021, 207, 1078-1086.  | 0.4 | 14        |
| 13 | Serial evaluation of the pharmacokinetics of ponatinib in patients with CML and Ph+ ALL. <i>International Journal of Hematology</i> , 2021, 114, 509-516.   | 0.7 | 2         |
| 14 | Properties and Distribution of IDH-1/2 Mutations in Acute Myeloid Leukemia By the Comprehensive Genomic Analysis. <i>Blood</i> , 2021, 138, 4447-4447.  | 0.6 | 0         |
| 15 | Efficacy and Safety of Bosutinib in Japanese Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: Final 3-Year Results of a Phase 2 Study. <i>Blood</i> , 2021, 138, 2557-2557.  | 0.6 | 0         |
| 16 | Regulatory T Cell as a Biomarker of Treatment-Free Remission in Patients with Chronic Myeloid Leukemia. <i>Cancers</i> , 2021, 13, 5904.  | 1.7 | 3         |
| 17 | Hematologic Malignancies (HM)-Screen-Japan 01: A Mutation Profiling Multicenter Study on Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 4457-4457.   | 0.6 | 4         |
| 18 | Clinical Significance of FLT3 Mutations in a Comprehensive NGS Multicenter Study of AML: HM-Screen-Japan 01. <i>Blood</i> , 2021, 138, 2313-2313.   | 0.6 | 1         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Genomic Analysis of <i>NPM1</i> Mutation and <i>KMT2A</i> ( <i>MLL</i> )-Rearrangement/Amplification in Japanese Patients with Acute Myeloid Leukemia: Hematologic Malignancies (HM)-Screen-Japan 01. <i>Blood</i> , 2021, 138, 4460-4460.                       | 0.6 | 0         |
| 20 | Patient and Physician Perspectives of Unmet Needs in CML - Designing the CML SUN Survey. <i>Blood</i> , 2021, 138, 4986-4986.  | 0.6 | 0         |
| 21 | Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells. <i>Journal of Experimental Medicine</i> , 2020, 217, .  | 4.2 | 58        |
| 22 | Multiple Myeloma-associated Ig Light Chain Crystalline Cast Nephropathy. <i>Kidney International Reports</i> , 2020, 5, 1595-1602.   | 0.4 | 7         |
| 23 | JSH Practical Guidelines for Hematological Malignancies, 2018: I. Leukemia-4. Chronic myeloid leukemia (CML)/myeloproliferative neoplasms (MPN). <i>International Journal of Hematology</i> , 2020, 112, 268-291.  | 0.7 | 21        |
| 24 | Prognostic effect of comorbidities in patients with chronic myeloid leukemia treated with a tyrosine kinase inhibitor. <i>Cancer Science</i> , 2020, 111, 3714-3725.   | 1.7 | 13        |
| 25 | Hypoxia-inducible hexokinase-2 enhances anti-apoptotic function via activating autophagy in multiple myeloma. <i>Cancer Science</i> , 2020, 111, 4088-4101.  | 1.7 | 34        |
| 26 | Cdc42 regulates cell polarization and contractile actomyosin rings during terminal differentiation of human erythroblasts. <i>Scientific Reports</i> , 2020, 10, 11806.  | 1.6 | 11        |
| 27 | An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia. <i>Blood</i> , 2020, 135, 2337-2353.   | 0.6 | 49        |
| 28 | Treatment outcomes of chronic-phase chronic myeloid leukemia with resistance and/or intolerance to a 1st-line tyrosine kinase inhibitor in Japan: the results of the New TARGET study 2nd-line. <i>International Journal of Hematology</i> , 2020, 111, 812-825. | 0.7 | 4         |
| 29 | Phase 2 study of bosutinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia. <i>International Journal of Hematology</i> , 2020, 112, 24-32.  | 0.7 | 10        |
| 30 | Nilotinib Vs. Dasatinib in Achieving MR4.5 for Newly Diagnosed Chronic Myeloid Leukemia: Results of the Prospective Randomized Phase 3 Study, JALSG CML212. <i>Blood</i> , 2020, 136, 40-41.   | 0.6 | 11        |
| 31 | Hypereosinophilic syndrome with abundant Charcot-Leyden crystals in spleen and lymph nodes. <i>Asia Pacific Allergy</i> , 2020, 10, e24.   | 0.6 | 9         |
| 32 | Comparative proteomic analysis of renal proteins from IgA nephropathy model mice and control mice. <i>Clinical and Experimental Nephrology</i> , 2020, 24, 666-679.  | 0.7 | 6         |
| 33 | Genetic Features of AML with <i>MLL</i> -Rearrangement and <i>NPM1</i> Mutation: An Interim-Analysis of HM-Screen-Japan 01. <i>Blood</i> , 2020, 136, 35-36.   | 0.6 | 0         |
| 34 | Interim Analysis of Hematologic Malignancies (HM)-Screen-Japan 01: A Mutation Profiling Multicenter Study of Patients with AML. <i>Blood</i> , 2020, 136, 2-3.   | 0.6 | 2         |
| 35 | Genomic Analysis of <i>FLT3</i> Mutations in a Comprehensive NGS Multicenter Study of AML: HM-Screen-Japan 01. <i>Blood</i> , 2020, 136, 32-34.  | 0.6 | 0         |
| 36 | Thrombocytopenia Caused by a Tea Beverage of <i>Taxus yunnanensis</i> (Chinese Yew). <i>Internal Medicine</i> , 2019, 58, 3153-3156.   | 0.3 | 1         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | High-throughput sequencing of IgG B-cell receptors reveals frequent usage of the rearranged IGHV4 $\alpha$ 28/IGHJ4 gene in primary immune thrombocytopenia. <i>Scientific Reports</i> , 2019, 9, 8645.   | 1.6 | 9         |
| 38 | Influence of ABCB1 polymorphisms on the pharmacokinetics and toxicity of lenalidomide in patients with multiple myeloma. <i>Medical Oncology</i> , 2019, 36, 55.  | 1.2 | 6         |
| 39 | Effect of low platelet HLA-C expression on donor-specific antibody depletion following platelet transfusion from a corresponding HLA donor. <i>Bone Marrow Transplantation</i> , 2019, 54, 1713-1716.   | 1.3 | 2         |
| 40 | ATP produced by anaerobic glycolysis is essential for enucleation of human erythroblasts. <i>Experimental Hematology</i> , 2019, 72, 14-26.e1.  | 0.2 | 17        |
| 41 | Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system. <i>International Journal of Hematology</i> , 2019, 109, 426-439. | 0.7 | 29        |
| 42 | ENESTop 192-week results: Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib (NIL).. <i>Journal of Clinical Oncology</i> , 2019, 37, 7005-7005.                           | 0.8 | 6         |
| 43 | 7. Diagnosis and Treatment of Chronic Myeloid Leukemia and Myeloproliferative Neoplasms. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2019, 108, 547-550.  | 0.0 | 0         |
| 44 | Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase. <i>Annals of Internal Medicine</i> , 2018, 168, 461.   | 2.0 | 105       |
| 45 | Phase II Clinical Trial of Lenalidomide and Dexamethasone Therapy in Japanese Elderly Patients With Newly Diagnosed Multiple Myeloma to Determine Optimal Plasma Concentration of Lenalidomide. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 301-309.                   | 1.0 | 9         |
| 46 | The localization of $\alpha$ -synuclein in the process of differentiation of human erythroid cells. <i>International Journal of Hematology</i> , 2018, 108, 130-138.  | 0.7 | 16        |
| 47 | The potential role of clarithromycin addition to lenalidomide and dexamethasone therapy (BiRd) in multiple myeloma. <i>Annals of Hematology</i> , 2018, 97, 1097-1099.  | 0.8 | 4         |
| 48 | Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia. <i>Experimental Hematology and Oncology</i> , 2018, 7, 9.                              | 2.0 | 21        |
| 49 | Switching to nilotinib is associated with deeper molecular responses in chronic myeloid leukemia chronic phase with major molecular responses to imatinib: STAT1 trial in Japan. <i>International Journal of Hematology</i> , 2018, 108, 176-183.                         | 0.7 | 3         |
| 50 | Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study. <i>International Journal of Hematology</i> , 2018, 107, 185-193.           | 0.7 | 72        |
| 51 | Therapeutic drug monitoring of ponatinib using a simple high-performance liquid chromatography method in Japanese patients. <i>Leukemia Research</i> , 2018, 64, 42-45.   | 0.4 | 23        |
| 52 | Hypoxia-inducible KDM3A addiction in multiple myeloma. <i>Blood Advances</i> , 2018, 2, 323-334.  | 2.5 | 50        |
| 53 | Safety and efficacy of high-dose ranimustine (MCNU) containing regimen followed by autologous stem cell transplantation for diffuse large B-cell lymphoma. <i>International Journal of Hematology</i> , 2018, 108, 510-515.   | 0.7 | 9         |
| 54 | Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan. <i>Haematologica</i> , 2018, 103, 1835-1842.  | 1.7 | 59        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 55 | Effects of polymorphisms in NR1I2, CYP3A4, and ABC transporters on the steady-state plasma trough concentrations of bosutinib in Japanese patient with chronic myeloid leukemia. <i>Medical Oncology</i> , 2018, 35, 90.                             | 1.2 | 6         |
| 56 | Long-term treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib: ENESTop 144-wk results.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7003-7003.    | 0.8 | 4         |
| 57 | Hypoxia-inducible microRNA-210 regulates the IRF4 oncogenic axis in multiple myeloma. <i>Cancer Science</i> , 2017, 108, 641-652.  | 1.7 | 31        |
| 58 | Long-term treatment with bosutinib in a phase 1/2 study in Japanese chronic myeloid leukemia patients resistant/intolerant to prior tyrosine kinase inhibitor treatment. <i>International Journal of Hematology</i> , 2017, 106, 398-410.            | 0.7 | 6         |
| 59 | Drug interaction between tacrolimus and nilotinib in a patient with chronic myeloid leukemia after renal transplant. <i>Clinical Case Reports (discontinued)</i> , 2017, 5, 605-607.   | 0.2 | 1         |
| 60 | Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1/2 study. <i>International Journal of Hematology</i> , 2017, 106, 385-397.   | 0.7 | 33        |
| 61 | TAFRO Syndrome with Bilateral Adrenal Hemorrhage. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2017, 106, 288-294.  | 0.0 | 5         |
| 62 | Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma. <i>Oncotarget</i> , 2017, 8, 7572-7585.   | 0.8 | 27        |
| 63 | Therapeutic drug monitoring enables safe and effective lenalidomide therapy in patients with multiple myeloma on hemodialysis. <i>Annals of Hematology</i> , 2016, 95, 2087-2088.  | 0.8 | 1         |
| 64 | Effects of CYP3A5 polymorphism on the pharmacokinetics of a once-daily modified-release tacrolimus formulation and acute kidney injury in hematopoietic stem cell transplantation. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 111-118.  | 1.1 | 12        |
| 65 | Erythroblast enucleation is a dynein-dependent process. <i>Experimental Hematology</i> , 2016, 44, 247-256.e12.  | 0.2 | 24        |
| 66 | Routine therapeutic drug monitoring of tyrosine kinase inhibitors by HPLC-UV or LC-MS/MS methods. <i>Drug Metabolism and Pharmacokinetics</i> , 2016, 31, 12-20.   | 1.1 | 41        |
| 67 | Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase According to Reasons for Switching from Imatinib to Nilotinib: Subgroup Analysis from ENESTop. <i>Blood</i> , 2016, 128, 792-792.                                | 0.6 | 16        |
| 68 | Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with second-line nilotinib (NIL): First results from the ENESTop study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7054-7054. | 0.8 | 6         |
| 69 | Disruption of CCL20-CCR6 interaction inhibits metastasis of advanced cutaneous T-cell lymphoma. <i>Oncotarget</i> , 2016, 7, 13563-13574.  | 0.8 | 21        |
| 70 | Hypereosinophilic Syndrome in the Tyrosine Kinase Inhibitor Era. <i>Internal Medicine</i> , 2015, 54, 551-552.   | 0.3 | 0         |
| 71 | A phase 1/2 study of bosutinib in Japanese adults with Philadelphia chromosome-positive chronic myeloid leukemia. <i>International Journal of Hematology</i> , 2015, 101, 154-164.   | 0.7 | 23        |
| 72 | Effect of CYP3A5 and ABCB1 polymorphisms on the interaction between tacrolimus and itraconazole in patients with connective tissue disease. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 1091-1097.                                  | 0.8 | 7         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 73 | The Genomic and Epigenomic Landscapes of Blast Crisis Transformation in Chronic Myeloid Leukemia. <i>Blood</i> , 2015, 126, 3737-3737.  | 0.6 | 3         |
| 74 | Functional Analysis of the CML Blast Crisis Transcriptome and Epigenome Using Crispr-CAS9 and Pharmacologic Approaches. <i>Blood</i> , 2015, 126, 2764-2764.  | 0.6 | 0         |
| 75 | Influence of UGT1A1 *6, *27, and *28 Polymorphisms on Nilotinib-induced Hyperbilirubinemia in Japanese Patients with Chronic Myeloid Leukemia. <i>Drug Metabolism and Pharmacokinetics</i> , 2014, 29, 449-454.   | 1.1 | 35        |
| 76 | A Limited Sampling Model to Estimate Exposure to Lenalidomide in Multiple Myeloma Patients. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 505-509.   | 1.0 | 5         |
| 77 | Multicenter phase II clinical trial of nilotinib for patients with imatinib-resistant or -intolerant chronic myeloid leukemia from the East Japan CML study group evaluation of molecular response and the efficacy and safety of nilotinib. <i>Biomarker Research</i> , 2014, 2, 6.              | 2.8 | 20        |
| 78 | Ponatinib Safety and Efficacy in Japanese Patients with Philadelphia Positive Leukemia: Update of a Phase 1/2 Study. <i>Blood</i> , 2014, 124, 5541-5541.   | 0.6 | 0         |
| 79 | Effect of itraconazole on the concentrations of tacrolimus and cyclosporine in the blood of patients receiving allogeneic hematopoietic stem cell transplants. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 1321-1329.  | 0.8 | 30        |
| 80 | Safety and efficacy of low-dose liposomal amphotericin B as empirical antifungal therapy for patients with prolonged neutropenia. <i>International Journal of Clinical Oncology</i> , 2013, 18, 983-987.  | 1.0 | 6         |
| 81 | A multicenter clinical study evaluating the confirmed complete molecular response rate in imatinib-treated patients with chronic phase chronic myeloid leukemia by using the international scale of real-time quantitative polymerase chain reaction. <i>Haematologica</i> , 2013, 98, 1407-1413. | 1.7 | 29        |
| 82 | Personalized Therapy of Tyrosine Kinase Inhibitors. <i>Japanese Journal of Clinical Pharmacology and Therapeutics</i> , 2013, 44, 225-228.  | 0.1 | 0         |
| 83 | Effective Steroid Pulse Therapy for mitigate the acute phase symptoms of Human herpesvirus 6 encephalitis after allogeneic hematopoietic stem cell transplantation: experience of two cases. <i>Journal of Hematopoietic Cell Transplantation</i> , 2013, 2, 75-79.                               | 0.1 | 0         |
| 84 | Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. <i>Haematologica</i> , 2012, 97, 903-906.   | 1.7 | 138       |
| 85 | Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation. <i>Journal of Hematology and Oncology</i> , 2012, 5, 23.   | 6.9 | 21        |
| 86 | H2-receptor antagonist influences dasatinib pharmacokinetics in a patient with Philadelphia-positive acute lymphoblastic leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 351-352.   | 1.1 | 9         |
| 87 | Bile acid is important for gastrointestinal absorption of nilotinib. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 1575-1576.  | 0.8 | 2         |
| 88 | Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 999-1004.  | 1.1 | 43        |
| 89 | A synthetic double-stranded RNA, poly I:C, induces a rapid apoptosis of human CD34+ cells. <i>Experimental Hematology</i> , 2012, 40, 330-341.  | 0.2 | 52        |
| 90 | Drug interaction between lenalidomide and itraconazole. <i>American Journal of Hematology</i> , 2012, 87, 338-339.  | 2.0 | 25        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 91  | Pharmacokinetics of nilotinib in imatinib-resistant/intolerant chronic myeloid leukemia patients on hemodialysis for chronic renal failure. <i>American Journal of Hematology</i> , 2012, 87, 451-451.   | 2.0 | 11        |
| 92  | A multicenter phase II study of bendamustine with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).. <i>Journal of Clinical Oncology</i> , 2012, 30, 8023-8023.  | 0.8 | 2         |
| 93  | Drug interaction of (S)-warfarin, and not (R)-warfarin, with itraconazole in a hematopoietic stem cell transplant recipient. <i>Clinica Chimica Acta</i> , 2011, 412, 2002-2006.   | 0.5 | 14        |
| 94  | Fatal hemorrhagic pneumonia caused by <i>Stenotrophomonas maltophilia</i> in a patient with non-Hodgkin lymphoma. <i>Journal of Infection and Chemotherapy</i> , 2011, 17, 858-862.  | 0.8 | 13        |
| 95  | Therapeutic Drug Monitoring of Imatinib for Chronic Myeloid Leukemia Patients in the Chronic Phase. <i>Pharmacology</i> , 2011, 87, 241-248.   | 0.9 | 36        |
| 96  | Quantitative Determination of Imatinib in Human Plasma with High-Performance Liquid Chromatography and Ultraviolet Detection. <i>Journal of Chromatographic Science</i> , 2011, 49, 412-415.   | 0.7 | 37        |
| 97  | High-performance liquid chromatography with solid-phase extraction for the quantitative determination of nilotinib in human plasma. <i>Biomedical Chromatography</i> , 2010, 24, 789-793.  | 0.8 | 30        |
| 98  | Early prediction of a long-term outcome by neutrophil-FISH in patients with CML receiving imatinib mesylate. <i>International Journal of Hematology</i> , 2010, 92, 559-561.   | 0.7 | 0         |
| 99  | Effect of oral itraconazole on the pharmacokinetics of tacrolimus in a hematopoietic stem cell transplant recipient with CYP3A5*3/*3. <i>American Journal of Hematology</i> , 2010, 85, 634-635.   | 2.0 | 9         |
| 100 | Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia. <i>Journal of Human Genetics</i> , 2010, 55, 731-737.                          | 1.1 | 147       |
| 101 | Dasatinib Cerebrospinal Fluid Concentration and Plasma Pharmacokinetics: Potential for Central Nervous System Prophylaxis In Philadelphia Chromosome-Positive Leukemia. <i>Blood</i> , 2010, 116, 1807-1807.   | 0.6 | 2         |
| 102 | Safety, Feasibility and Efficacy of High Dose Ranimustine (MCNU), Carboplatin, Etoposide, and Cyclophosphamide (MCVC) Therapy Followed by Autologous Stem Cell Transplantation for Malignant Lymphoma.. <i>Blood</i> , 2010, 116, 4588-4588.             | 0.6 | 2         |
| 103 | Kidney-limited intravascular large B cell lymphoma: a distinct variant of IVLBCL?. <i>International Journal of Hematology</i> , 2009, 89, 533-537.   | 0.7 | 24        |
| 104 | Clinical features of adult acute leukemia with 11q23 abnormalities in Japan: a co-operative multicenter study. <i>International Journal of Hematology</i> , 2008, 87, 195-202.   | 0.7 | 16        |
| 105 | Phagocytosis of co-developing neutrophil progenitors by dendritic cells in a culture of human CD34+ cells with granulocyte colony-stimulating factor and tumor necrosis factor- $\alpha$ . <i>International Journal of Hematology</i> , 2008, 88, 64-72. | 0.7 | 3         |
| 106 | Itraconazole Oral Solution Enhanced Vincristine Neurotoxicity in Five Patients with Malignant Lymphoma. <i>Internal Medicine</i> , 2008, 47, 651-653.  | 0.3 | 24        |
| 107 | Low Level of Serum Haptoglobin in Patients with Acquired Bone Marrow Failure (BMF) Syndromes.. <i>Blood</i> , 2007, 110, 3774-3774.  | 0.6 | 0         |
| 108 | Low Dose and Standard Dose of Imatinib Therapy for Patients with Chronic Myeloid Leukemia in Akita Prefecture, Japan.. <i>Blood</i> , 2007, 110, 4575-4575.  | 0.6 | 0         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 109 | BCR-ABL Activates IGF-1 Expression and Signaling in Chronic Myelogenous Leukemia Blast Crisis Cell Lines.. Blood, 2006, 108, 1932-1932.   | 0.6 | 16        |
| 110 | RIZ1 Is Downregulated during CML Progression and Displays Tumor Suppressor Properties in CML Cell Lines.. Blood, 2006, 108, 2134-2134.  | 0.6 | 1         |
| 111 | Clinical Analysis of Adult Acute Leukemia with Rearrangements of the 11q23/MLL: Multicenter Co-Operative Study.. Blood, 2006, 108, 2354-2354.   | 0.6 | 0         |
| 112 | Phagocytosis of Co-Developing Neutrophil Progenitors by Dendritic Cells in Culture with Granulocyte-Colony Stimulating-Factor and Tumor Necrosis Factor- $\alpha$ : Induction of T Regulatory Cells by Co-Developing Dendritic Cells.. Blood, 2006, 108, 1720-1720.                         | 0.6 | 0         |
| 113 | Fluorescence In Situ Hybridization Monitoring of BCR-ABL-Positive Neutrophils in Chronic-Phase Chronic Myeloid Leukemia Patients during the Primary Stage of Imatinib Mesylate Therapy. International Journal of Hematology, 2005, 81, 235-241.   | 0.7 | 14        |
| 114 | A Clinical Analysis of 52 Adult Patients With Hemophagocytic Syndrome: The Prognostic Significance of the Underlying Diseases. International Journal of Hematology, 2001, 74, 209-213.  | 0.7 | 153       |
| 115 | A Clinicopathological Study of 20 Patients With T/Natural Killer (NK)-Cell Lymphoma-Associated Hemophagocytic Syndrome With Special Reference to Nasal and Nasal-Type NK/T-Cell Lymphoma. International Journal of Hematology, 2001, 74, 303-308.   | 0.7 | 93        |
| 116 | Involvement of natural killer cells in patients with myelodysplastic syndrome carrying monosomy 7 revealed by the application of fluorescence in situ hybridization to cells collected by means of fluorescence-activated cell sorting. British Journal of Haematology, 2000, 110, 876-879. | 1.2 | 32        |
| 117 | Molecular heterogeneity of the NUP98/HOXA9 fusion transcript in myelodysplastic syndromes associated with t(7;11)(p15;p15). British Journal of Haematology, 1999, 107, 600-604.   | 1.2 | 40        |
| 118 | Molecular features of a new human lymphoma cell line carrying both BCL2 and BCL6 gene rearrangements. Oncogene, 1998, 17, 971-979.  | 2.6 | 15        |
| 119 | Fluorescence In Situ Hybridization of Progenitor Cells Obtained by Fluorescence-Activated Cell Sorting for the Detection of Cells Affected by Chromosome Abnormality Trisomy 8 in Patients With Myelodysplastic Syndromes. Blood, 1998, 92, 2886-2892.                                      | 0.6 | 67        |
| 120 | Lineage Involvement of Stem Cells Bearing the Philadelphia Chromosome in Chronic Myeloid Leukemia in the Chronic Phase as Shown by a Combination of Fluorescence-Activated Cell Sorting and Fluorescence In Situ Hybridization. Blood, 1998, 92, 4758-4763.                                 | 0.6 | 161       |
| 121 | Lineage Involvement of Stem Cells Bearing the Philadelphia Chromosome in Chronic Myeloid Leukemia in the Chronic Phase as Shown by a Combination of Fluorescence-Activated Cell Sorting and Fluorescence In Situ Hybridization. Blood, 1998, 92, 4758-4763.                                 | 0.6 | 10        |
| 122 | Fluorescence In Situ Hybridization of Progenitor Cells Obtained by Fluorescence-Activated Cell Sorting for the Detection of Cells Affected by Chromosome Abnormality Trisomy 8 in Patients With Myelodysplastic Syndromes. Blood, 1998, 92, 2886-2892.                                      | 0.6 | 3         |
| 123 | Rearrangements of the BCL6 Gene and Chromosome Aberrations Affecting 3q27 in 54 Patients with Non-Hodgkin's Lymphoma. Leukemia and Lymphoma, 1997, 27, 329-334.   | 0.6 | 18        |
| 124 | 11q23 Aberration is an additional chromosomal change in de novo acute leukemia after treatment with etoposide and mitoxantrone. , 1996, 53, 264-266.  |     | 14        |
| 125 | Acute Myelogenous Leukemia Associated with a Mediastinal Tumor. Leukemia and Lymphoma, 1993, 12, 143-146.   | 0.6 | 11        |